1. "Elsevier Inc."
  2. "Hematologic Malignancies Research"
Formats
  1. Meeting Abstract (143)
  2. Journal Article (107)
  3. Review (10)
  4. Editorial (5)
  5. Book Section (3)
  6. Research Letter (2)
  7. Book Whole (1)
  8. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (272)
  2. Hematologic Malignancies Research (272)
  3. Department of Medicine (246)
  4. Hematologic Malignancies, Division of (213)
  5. GSK Faculty (190)
  6. Sloan Kettering Institute Faculty (135)

More Groups

People
  1. Alexander Lesokhin (65)
  2. Sergio Giralt (62)
  3. Katharine Hsu (50)
  4. David Chung (49)
  5. Heather Landau (49)
  6. Michel Sadelain (49)

More People

Years
  1. 2023 (23)
  2. 2022 (14)
  3. 2021 (13)
  4. 2020 (22)
  5. 2019 (30)
  6. 2018 (20)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (80)
  2. Clinical Lymphoma, Myeloma and Leukemia (71)
  3. Blood Cells, Molecules, and Diseases (12)
  4. Journal of Thoracic Oncology (12)
  5. Best Practice and Research: Clinical Haematology (11)
  6. Cell Metabolism (11)

More Publications

Publishers
  1. Elsevier Inc. (272)

Results (272)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse national health and nutrition examination survey (NHANES) case-control study
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S.; Lesokhin, A.; Moysich, K.; Shah, U.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology
    Meeting Abstract

    Maclachlan, K.; Blaney, P.; Gagler, D.; Boyle, E.; Diamond, B.; Shah, U.; Korde, N.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Jagannath, S.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: Post-hoc analysis from MagnetisMM-3
    Meeting Abstract

    Leleu, X.; Bahlis, N.; Rodríguez-Otero, P.; Quach, H.; Touzeau, C.; Depaus, J.; Iida, S.; Hänel, M.; Wrobel, T.; Leip, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma
    Meeting Abstract

    Shah, G.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save